Hemodynamics and epoprostenol use are associated with thrombocytopenia in pulmonary arterial hypertension

Chest
Kelly M ChinL J Rubin

Abstract

Thrombocytopenia develops in some patients with advanced pulmonary arterial hypertension (PAH) while receiving IV epoprostenol therapy. In this study, we evaluate whether epoprostenol use, other PAH medication use, hemodynamics, or PAH etiology are associated with thrombocytopenia in PAH. Platelet counts were evaluated in 47 PAH patients receiving IV epoprostenol, and in 44 patients with an inadequate response to initial therapy with oral agents in a cross-sectional study. Associations between thrombocytopenia (platelet count < 150,000/mL) and epoprostenol use, hemodynamics, PAH etiology, and use of other PAH medications were evaluated in univariable and multivariable analyses. PAH subtypes included idiopathic (69%), fenfluramine (18%), connective tissue disease (10%), and congenital heart disease (2%)-associated PAH. Thrombocytopenia was observed in 34% of patients treated with epoprostenol, compared with 15% of patients receiving oral therapy (odds ratio [OR], 2.9; p < 0.05), and the association between epoprostenol and thrombocytopenia remained significant after adjustment for differences in hemodynamics (OR, 5.0; p < 0.05). Right atrial pressure (OR, 1.12 per mm Hg; p < 0.05) and mixed venous oxygen saturation (Svo(2)) [OR,...Continue Reading

References

Sep 17, 1976·Deutsche medizinische Wochenschrift·J HeckG Gehrmann
Jul 1, 1982·Cardiovascular Research·A M PetersJ P Lavender
Feb 1, 1996·The New England Journal of Medicine·R J BarstUNKNOWN Primary Pulmonary Hypertension Study Group
Sep 9, 1999·Liver Transplantation and Surgery : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·J Y FindlayM K Porayko
Feb 22, 2001·Annals of Internal Medicine·M A RizviJ N George
Apr 9, 2002·The European Respiratory Journal·M BeghettiP C Rimensberger
Sep 10, 2005·American Journal of Respiratory and Critical Care Medicine·Mardi Gomberg-MaitlandRobyn J Barst
Mar 2, 2006·The European Respiratory Journal·I M RobbinsR J Barst
May 8, 2007·Prostaglandins & Other Lipid Mediators·Huang-Wei ShenWai-Ming Kan
Sep 18, 2007·Chest·Shelley Shapiro, Nicholas S Hill

❮ Previous
Next ❯

Citations

Apr 2, 2011·Advances in Therapy·Jean-Luc Vachiéry
Aug 7, 2010·Southern Medical Journal·Jose A Cantu, Zeenat Safdar
May 20, 2011·Circulation·Steven M KawutUNKNOWN ASA-STAT Study Group
Oct 19, 2013·Pharmacology & Therapeutics·David MontaniMarc Humbert
Aug 30, 2014·Heart & Lung : the Journal of Critical Care·Mohammad Khalid MojadidiRonald Zolty
Aug 21, 2015·Expert Opinion on Pharmacotherapy·Swanny PerrinOlivier Sitbon
Nov 17, 2010·Expert Opinion on Drug Metabolism & Toxicology·Marie-Camille ChaumaisDavid Montani
Jan 10, 2012·The American Journal of the Medical Sciences·Waseem ToumaGanesh C Kudva
Jan 11, 2016·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Caroline O'ConnellOlivier Sitbon
Jul 16, 2010·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·Kristina T KudelkoVinicio De Jesus Perez
Jun 8, 2012·Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·Zeenat SafdarNorman Sussman
Oct 13, 2012·Therapeutic Advances in Respiratory Disease·Zeenat Safdar
Nov 28, 2014·World Journal of Hepatology·Yu YamashitaMasaharu Nishimura
Jun 24, 2021·Pulmonary Circulation·Sarah CullivanSean P Gaine
Dec 17, 2009·Current Opinion in Rheumatology

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.